BG Medicine, Inc. Announces Closing of Public Offering and Exercise of Over-Allotment Option

BG Medicine, Inc. Announces Closing of Public Offering and Exercise of
Over-Allotment Option

WALTHAM, Mass., Jan. 30, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc.
(Nasdaq:BGMD), a diagnostics company focused on the development and
commercialization of novel cardiovascular tests, today announced the closing
of its previously announced public offering of 6,000,000 shares of its common
stock, as well as 900,000 additional shares of its common stock pursuant to
the full exercise of the over-allotment option granted to the underwriter. 

The shares were sold at the public offering price of $2.00 per share and the
company estimates the aggregate net proceeds to the company will be
approximately $12.8 million, after deducting underwriting discounts and
commissions and other estimated offering expenses.

Lazard Capital Markets LLC acted as the sole book-running manager for the

The shares were sold by means of BG Medicine's existing shelf registration
statement on Form S-3, a prospectus and related prospectus supplement, all as
filed with the Securities and Exchange Commission (the "SEC"). Copies of the
prospectus supplement may be obtained from the offices of Lazard Capital
Markets LLC, 30 Rockefeller Plaza, New York, NY 10020 or via telephone at
(800) 542-0970.

This press release does not constitute an offer to sell or a solicitation of
an offer to buy any securities of BG Medicine, nor shall there be any sale of
securities in any state or jurisdiction in which such an offer, solicitation
or sale would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.

About BG Medicine

BG Medicine, Inc. (Nasdaq:BGMD) is a diagnostics company focused on the
development and commercialization of novel cardiovascular tests to address
significant unmet medical needs, improve patient outcomes and reduce
healthcare costs. The Company has two products: the BGM Galectin-3^® test for
use in patients with chronic heart failure is available in the United States
and Europe; and the CardioSCORE™ test for the risk prediction of major
cardiovascular events will be launched in Europe in the first half of 2013.
For additional information about BG Medicine, heart failure and galectin-3
testing, please visit and

The BG Medicine Inc. logo is available at

Cautionary Statement Regarding Forward-Looking Statements

This communication includes forward-looking statements regarding events,
trends and business prospects, which may affect BG Medicine's future operating
results and financial position. Such statements, including, but not limited
to, those regarding BG Medicine's estimates of its approximate net proceeds
from the public offering and expenses payable in connection with the public
offering, involve known and unknown risks that relate to BG Medicine's future
events or future financial performance and the actual results could differ
materially from those discussed in this communication. Risks and uncertainties
that may cause BG Medicine's actual results to differ materially from those
discussed in this communication can be found in the "Risk Factors" section of
BG Medicine's prospectus supplement filed on January 25, 2013 relating to the
public offering, its Current Report on Form 8-K filed on January 24, 2013, and
the other filings BG Medicine periodically makes with the Securities and
Exchange Commission. Readers are cautioned not to place undue reliance on
these forward-looking statements that speak only as of the date hereof, and BG
Medicine assumes no responsibility to update or revise any forward-looking
statements contained in this communication to reflect events, trends or
circumstances after the date of this communication.

CONTACT: Chuck Abdalian
         EVP & Chief Financial Officer
         (781) 434-0210

BG Medicine Inc. logo
Press spacebar to pause and continue. Press esc to stop.